TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Torrent Pharmaceuticals reported strong revenue growth for Q4 FY26 with total revenues of Rs 4,197 crore, up 43% year-on-year from Rs 2,959 crore. For the full year FY26, total revenue grew 21% to Rs 13,980 crore from Rs 11,516 crore. Brazil was the fastest-growing market with 68% growth in Q4 (Rs 798 crore), while India grew 31% to Rs 396 crore. The United States posted more modest growth of 16% to Rs 333 crore in Q4. Germany revenues rose 30% to Rs 455 crore in the quarter. The presentation was made to analysts following the audited financial results for the quarter and year ended 31st March, 2026.
The strong double-digit growth across all major markets signals robust business momentum, which could be positive for the stock. However, investors should note the more moderate US growth compared to other regions when evaluating geographic diversification.